Loading
Life sciences · Journal article
Open Access Research Journal of Biology and Pharmacy · October 15, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Breast cancer remains a major cause of cancer-related mortality among women worldwide. Although doxorubicin is widely used in chemotherapy, its clinical application is limited by cardiotoxicity, systemic toxicity, and non-specific drug distribution. pH-responsive polymeric nanoparticles offer a promising approach for targeted drug delivery by releasing doxorubicin in the acidic tumor microenvironment while maintaining stability under physiological conditions. Biodegradable polymers, including PLGA, PEG, chitosan, and poly(β-amino esters), have been investigated for developing these nanocarriers. Preclinical studies indicate improved intracellular drug delivery, enhanced antitumor activity, and potential reductions in systemic toxicity. This review highlights recent advances in the design, development, and therapeutic applications of pH-responsive polymeric nanoparticles for doxorubicin delivery in breast cancer, along with challenges in safety, clinical translation, and regulatory approval. These systems hold considerable potential for improving targeted cancer therapy.